GVK Bio have extended their biomarker database (GOBIOM) license to the biomarker qualification group of the US Food and Drug Administration (US FDA).
The GOBIOM database is a comprehensive collection of all the clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. It contains information on 12,000 biomarkers comprising of biochemical, genomic, imaging, metabolite, cellular and physiological markers with multiple data points covering experimental, analytical, clinical and statistical data with their qualifications under different medical interventions. According to GVK Bio, the GOBIOM database, which has the latest and updated information on all the biomarkers reported in various clinical and preclinical studies, will be of enormous use to US FDA in their qualification process.
The license has been extended for a period of one year and the license is perpetual in nature. Financial terms of the same has not been disclosed.
